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(Part 1. Prevalence, types, causes and effects was published in volume 2 issue 3 August 2009 of this Bulletin) 
 
Assessment 
Include the following: 
 Confirmation of hypertension  
 Risk factors for cardiovascular disease 
 Underlying cause(s) 
 End organ damage 
 Indications and contraindications for anti-
hypertensive drugs 
History 
A thorough history is essential - note particularly: 
1. Age, gender, family history 
2. Drugs: non-steroidal anti-inflammatory drugs, 
oral contraceptives, steroids, liquorice, 
sympathomimetics e.g. cocaine or epinephrine 
contained in cold remedies and cough 
medicines. 
3. Renal disease:  
 present, past and family history 
 history of haematuria and /or proteinuria 
4. Paroxysmal (intermittent) symptoms 
(?phaeochromocytoma) 
5. Muscle weakness, polyuria (?Conn’s syndrome) 
6. Rounded face and abdominal obesity 
(?Cushing’s syndrome) 
7. Cardiovascular risk factors and co-morbidities:  
 Overweight 
 Excess alcohol intake (>3 units/day for men, 
>2 units/day for women) 
 Cigarette smoking 
 Excess salt intake (>10g/day) 
 Diabetes mellitus 
 Dyslipidaemia (arcus cornealis, xantholasmata). 
8. Complications or end organ damage:  
 “Stroke”,  transient ischaemic attack (TIA) 
 Coronary artery disease, heart failure  
 Peripheral vascular disease 
 Visual problems 
 Renal disease. 
Physical examination 
1. Confirm the hypertension with repeated 
measurements over about four weeks. This 
may not be feasible where travelling to clinics is 
difficult - and may not be needed if there is end 
organ damage and malignant hypertension.  
2. Look for secondary causes (see Part 1). 
3. Record cardiovascular abnormalities: 
 Peripheral pulses 
 Radio-femoral delay, diminished femoral pulses 
with low femoral blood pressure (BP) (aortic 
coarctation) 
 Carotid and abdominal arterial bruits 
 Aortic aneurysm.  
4. Identify end organ damage: 
 Brain: motor or sensory defects 
 Retinal fundoscopic abnormalities 
 Heart: displacement of apical impulse, 
dysrhythmias, sounds and murmurs, 
ventricular gallop, pulmonary rales, 
peripheral oedema 
 Peripheral arterial pulses: absence, reduction or 
asymmetry, ischaemic skin lesions. 
5. Identify other conditions (co-morbidities):  
 High Body Mass Index (BMI). [BMI = weight 
in kg/height in meters²] BMI >25 = 
overweight; BMI >30 = obesity 
 High abdominal girth measured through the 
umbilicus. A value of >88centimetres for 
females and >102centimetres for males is 
considered an independent risk factor for 
cardiovascular disease 
 Bronchial asthma and chronic obstructive 
pulmonary disease (COPD): These are 
considered contraindications to beta blocker 
use. COPD is rare in black populations. 
 Investigations 
Routine Tests 
These should be available in most health centres: 
 Haemoglobin, haematocrit, ESR. 
 Urine “stix” test for proteinuria, haematuria, 
and glycosuria. 
The following are desirable but are less likely to be 
available: 
 Blood glucose (preferable fasting) 
 Serum urea and creatinine 
 Electrolytes, calcium and phosphate 
 Estimated creatinine clearance 
 Serum uric acid 
 Lipid profile 
 Electrocardiogram for cardiac rhythm and 
evidence of  left ventricular hypertrophy 
 Echocardiogram if cardiac structural 
abnormalities suspected. 
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Consider referral to a specialist for extended 
evaluation if there are these conditions: 
 Age <40 years 
 Severe hypertension with end organ damage 
 Poorly controlled hypertension 
 Suspected secondary hypertension. 
Indications for drug therapy 
1. Sustained systolic blood pressure (BP) 
>160mmHg or sustained diastolic BP 
>100mmHg despite non-pharmacological 
measures.  
2. Sustained systolic BP 140–159mmHg or 
diastolic blood pressure 90–99mmHg if  there is:     
 end organ damage or  
 diabetes mellitus.  
A target systolic BP <140mmHg and diastolic blood 
pressure <85mmHg is ideal. For patients with 
diabetes mellitus a target of 130/80mmHg is ideal.  
Non - pharmacological measures 
Attempt non-pharmacological methods of lowering 
BP in patients with mild hypertension but no 
cardiovascular complications or end organ damage. 
Start non-pharmacological measures in parallel with 
drug therapy in patients with severe hypertension 
(see British Hypertension Society guidelines – see 
website below). 
Benefits of non-pharmacological measures  
 Lowers BP as much as drug monotherapy 
 Reduces the need for drug therapy 
 Enhances the antihypertensive effect of drugs 
 Reduces the need for multiples drug regimens 
 Reduces overall cardiovascular risk. 
Non-pharmacological measures recommended 
by the British Hypertension Society 
That lower BP: 
 Weight reduction – aim for Body Mass Index  
20-25 Kg/m² 
 Reduced salt intake to <100 mmol/day (<6g 
NaCl or <2.4 g Na+/day. One flat 
teaspoonful = ~6g salt) 
 Reduced alcohol consumption to ≤ 3 units/day 
for men and ≤ 2 units/day for women (500 
ml beer = ~2 units) 
 Regular aerobic exercise (brisk walking rather 
than weightlifting for ≥30 minutes per day), 
on at least three days each week 
 At least five portions of fruit and vegetable each 
day (e.g. banana, mango, tomato, green 
leaves) 
 Reduced total fat and saturated fat intake. 
Saturated fats come mainly from animal 
foods such as milk and meat. 
That reduce cardiovascular risk: 
 Stopping smoking 
 Reducing total fat intake and replacing saturated 
fats with unsaturated fats. Unsaturated fats 
and oils come from plant foods and fish. 
Pharmacological therapy 
Classes of antihypertensive drugs 
The main purpose of treating hypertension is to 
reduce the incidence of cardiovascular (especially left 
ventricular failure), cerebrovascular disease 
(“stroke”) and renal failure. The five major classes of 
antihypertensive drugs are: 
 Diuretics (e.g. thiazide diuretics) 
 Calcium channel blockers (e.g. nifedipine) 
 Angiotensin converting enzyme inhibitors 
(ACEI) (e.g. lisinopril) 
 Angiotensin receptor antagonists (e.g. losartan)  
 Beta blockers (e.g. atenolol) 
Other antihypertensive drugs are: 
 Alpha receptor antagonists (e.g. prazosin) 
 Vasodilators (e.g. hydralazine) 
 Mineralocorticoid receptor antagonists (e.g. 
spironolactone) 
 Sympatholytics (e.g. clonidine, alpha 
methyldopa). 
The choice of antihypertensive drug (s) 
Factors influencing the choice of antihypertensive 
drug (s) are: 
 Age 
 Ethnicity 
 Co-morbidities e.g. diabetes mellitus, renal 
disease, peripheral arterial disease, “stroke”, 
prostate disease, obesity, pregnancy 
 Contraindications  e.g. beta blockers in 
bronchial asthma 
 Cardiovascular risk profile e.g. ischaemic heart 
disease 
 Severity of hypertension and presence of end 
organ damage 
 Etiology of hypertension – e.g. Cushing’s 
disease, renal artery stenosis 
 Side effects to previous treatment e.g. angio-
oedema with an ACEI 
 Drug compliance of patient 
 Socio-economic status 
 Economic factors and sustainable supply of 
drug(s) chosen. 
 Patient’s choice. 
The ideal drug is one that is given once each day, 
lowers the BP satisfactorily without significant side 
effects, has a sustainable supply and is not expensive. 
“ABCD” treatment Algorithm  
Most patients require more than one drug to control 
BP. The British Hypertension Society recommends 
an algorithm based on the AB/CD rule to assist with 
the selection of drug schedules. The idea of the 
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AB/CD algorithm is based upon the broad 
classification of hypertension into: 
1. High renin hypertension 
2. Low renin hypertension 
Therefore BP is best initially treated by one of 2 
categories of drugs: 
1. Drugs which inhibit the renin-angiotensin 
system (e.g. ACE inhibitors, Angiotensin 
receptors blockers or Beta blockers) or 
2. Drugs which do not inhibit the renin-
angiotensin system (e.g. Calcium antagonists or 
Diuretics). 
 
Because African (black) patients of all ages tend to 
have low renin levels, initial therapy should be a 
calcium-channel blocker or a thiazide diuretic. If a 
second drug is required, add an ACE inhibitor (or an 
angiotensin-II receptor antagonist if an ACE 
inhibitor is not tolerated).  
 
If treatment with three drugs is required, use a 
combination of ACE inhibitor (or angiotensin-II 
receptor antagonist), calcium-channel blocker and 
thiazide diuretic. 
If blood pressure remains uncontrolled on adequate 
doses of three drugs, consider adding a fourth 
and/or seeking expert advice.   
If a fourth drug is required, consider one of the 
following:  
 Beta-blocker    
 Selective alpha-blocker. 
Beta-blockers are not a preferred initial therapy as 
they are less effective in reducing major 
cardiovascular and cerebrovascular events. However, 
beta-blockers may be considered in younger people, 
particularly:  
 Those with an intolerance or contraindication to 
ACE inhibitors and Angiotensin-II receptor 
antagonists or  
 Women of child-bearing potential or  
 People with evidence of increased sympathetic 
drive. 
If therapy is initiated with a beta-blocker and a 
second drug is required, add a calcium-channel 
blocker. However if a beta-blocker is withdrawn, the 
dose should be stepped down gradually.  
Offer patients with isolated systolic hypertension 
(systolic BP 160 mmHg or more) the same treatment 
as patients with both raised systolic and diastolic 
blood pressure. 
Offer patients over 80 years old the same treatment 
as other patients over 55 years, taking account of any 
co-morbidity and their existing burden of drug use. 
 
 
Other medications for hypertensive 
patients 




1. Aspirin: use 75 mg daily if patient is aged ≥50 
years with BP controlled to <150/90 mmHg 
                                                     
1 This advice is based on Western studies and how far this 
practice should be extended in Africa is uncertain. Facilities 
for the measurement of blood cholesterol levels and supplies 
of a statin (e.g. simvastatin) are unlikely to be available so the 
management of hyperlipidaemia is not usually an option. 
 
and end organ damage, diabetes mellitus, or 10 
year risk of cardiovascular disease of ≥20%. 
(Measured by using the new Joint British 
Societies cardiovascular disease risk chart – see 
http://www.bhsoc.org/resources/prediction_ch
art.htm). 
2. Statin: use sufficient doses to reach cholesterol 
targets if patient is aged up to 80 years, with a 10 
year risk of cardiovascular disease of ≥20% and 
with total cholesterol concentration 
≥3.5mmol/l. 
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Secondary (including patients with type 2 
diabetes) 
1. Aspirin: use for all patients unless 
contraindicated. 
2. Statin: use sufficient doses to reach cholesterol 
targets if patient is aged up to 80 years with a 
total cholesterol concentration ≥3.5 mmol/l. 
Hypertension in black patients is different 
Hypertension occurs more frequently in black 
populations and is associated with: 
 a higher incidence of cerebrovascular and renal 
complications (end-stage renal failure is up to 20 
times more common) 
 a two-fold higher incidence of left ventricular 
hypertrophy with an increased risk of left 
ventricular failure. 
Salt (sodium) handling is different and associated 
with an expanded plasma volume and a higher 
prevalence of low plasma renin activity.  
Management of hypertension in black patients 
Non-pharmacological management 
Lifestyle and non-pharmacological interventions may 
significantly reduce blood pressure hence minimising 
the need for antihypertensive drugs. 
So advise patients to: 
 Eat less salt: Sodium restriction to an intake of 
<100 mmol day (i.e. total of one teaspoon/day) 
may have the same effect as a low-dose thiazide 
diuretic.  
 Lose weight: Black hypertensives are often 
obese and a fall in weight usually leads to a 
reduced blood pressure.  
 Drink less alcohol: Even moderate alcohol 
ingestion (three to five drinks daily) is associated 
with a raised blood pressure in black patients.  
 Take more exercise. 
 
Pharmacological management  
Diuretics: A thiazide diuretic (e.g. 
bendroflumethiazide 2.5mg daily) is the first-line 
treatment in most black hypertensives.  However 
the clinician should be aware of potential adverse 
metabolic effects: hypokalaemia, hyperlipidaemia 
and glycaemic control in diabetics.  
Beta-blockers: Beta-blockers (e.g. atenolol) are less 
effective in black hypertensives although younger 
patients may be more responsive than elderly 
ones. 
Angiotensin-converting enzyme (ACE) 
inhibitors: ACE inhibitors (e.g. captopril) appear 
less effective when used alone in black patients 
although this is eliminated by the addition of a 
diuretic. ACE inhibitors remain the first-line anti-
hypertensive agents in patients with diabetic 
nephropathy, particularly in the presence of 
proteinuria. The complication of ACE-inhibitor-
induced angio-oedema is more common in black 
patients. 
Calcium channel blockers: Calcium channel 
blockers (e.g. nifedipine) are highly effective. 
Verapamil is also a calcium channel blocker. It 
must never be used with a beta blocker because 
the two together may have a serious negative 
effect on cardiac function. 
Alpha-blockers: Alpha-receptor-blocking agents 
(e.g. doxazocin) reduce blood pressure by 
reducing peripheral vascular resistance. However, 
the addition of a diuretic is often required.  
Angiotensin receptor antagonists: There is limited 
information concerning the efficacy and 
tolerability of the angiotensin receptor 
antagonists (e.g. losartan) in black patients.  
In view of the high prevalence of hypertension and 
associated complications in the black population 
consider starting effective screening programmes.  
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